These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27913499)

  • 1. Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma.
    Moskowitz C
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):331-338. PubMed ID: 27913499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for the treatment of Hodgkin lymphoma.
    Donato EM; Fernández-Zarzoso M; De La Rubia J
    Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
    Khan N; Moskowitz AJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
    Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
    Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic agents for relapsed classical Hodgkin lymphoma.
    von Keudell G; Younes A
    Br J Haematol; 2019 Jan; 184(1):105-112. PubMed ID: 30536386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.
    Moskowitz AJ
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):207-212. PubMed ID: 30504312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent treatment advances in Hodgkin lymphoma: a concise review.
    Arulogun S; Hertzberg M; Gandhi MK
    Intern Med J; 2016 Dec; 46(12):1364-1369. PubMed ID: 26929077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
    Eyre TA; Phillips EH; Linton KM; Arumainathan A; Kassam S; Gibb A; Allibone S; Radford J; Peggs K; Burton C; Stewart G; LeDieu R; Booth C; Osborne WL; Miall F; Eyre DW; Ardeshna KM; Collins GP
    Br J Haematol; 2017 Nov; 179(3):471-479. PubMed ID: 28857136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic hematopoietic stem cell transplantation following treatment with brentuximab vedotin for refractory Hodgkin lymphoma].
    Yamane Y; Koda Y; Kohashi S; Kato J; Hashida R; Sakurai M; Toyama T; Kikuchi T; Okayama M; Kasahara H; Karigane D; Shimizu T; Okamoto S; Mori T
    Rinsho Ketsueki; 2017; 58(7):755-759. PubMed ID: 28781270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
    Bartlett NL
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
    Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
    Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
    Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
    Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M; Gibb A; Radford J; Linton K
    Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
    [No Abstract]   [Full Text] [Related]  

  • 20. The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.
    Grover NS; Dittus C; Thakkar A; Beaven AW
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):510-518. PubMed ID: 38066906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.